18.5亿拿下控股权，万可欣生物入主康华生物

Core Viewpoint - The transfer of shares in Kanghua Biological by its major shareholders to Wankexin Biological marks a significant change in control, with implications for the company's governance and future performance [1][2] Group 1: Share Transfer Details - Kanghua Biological's major shareholders, including Wang Zhentao and Aokang Group, plan to transfer a total of 28.4666 million shares, representing 21.91% of the total share capital, to Wankexin Biological at a price of 65.03 yuan per share, totaling 1.851 billion yuan [1] - Following the transaction, Aokang International will exit completely, and Kangyue Qiming's stake will decrease to 0.58%, while Wankexin Biological will hold 29.99% of the voting rights [1] - The control of Kanghua Biological will shift from Wang Zhentao to Wankexin Biological, which has no actual controller [1] Group 2: Financial Performance and Commitments - Aokang Group and Wang Zhentao have made performance commitments, ensuring that Kanghua Biological's net profit for 2025 and 2026 will not be less than 728 million yuan, with R&D expenses during this period totaling at least 260 million yuan [2] - Kanghua Biological's main business focuses on the research, production, and sales of human vaccines, with its core product being the freeze-dried human rabies vaccine [2] - The company's financial performance has been declining, with net profits decreasing for three consecutive years, and a significant drop in revenue and profit in the first quarter of the current year [2]